Application of PCV2 in preparation of oncolytic virus

By using PCV2 as an oncolytic virus, the problems of low delivery efficiency and safety of existing viral vectors in tumor treatment have been solved, achieving efficient and safe oncolytic effects on various human tumor cells, and is applicable to the treatment of cancers such as lung cancer and cervical cancer.

CN121759417APending Publication Date: 2026-03-31SOUTH CHINA AGRICULTURAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202610008478.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-05
Publication Date
2026-03-31

AI Technical Summary

Technical Problem

Existing oncolytic virus vectors face technical bottlenecks in tumor treatment, such as low delivery efficiency, weakened pre-existing immunity, and gene modification affecting replication efficiency. There is a lack of efficient and safe tumor-specific viral vectors.

Method used

Using porcine circovirus type II (PCV2) as an oncolytic virus, leveraging its high infectivity for human tumor cells, low pre-existing immune barrier, safety profile, and structural stability, we enhanced its targeting and immune activation potential against tumor cells through genetic modification, thereby achieving specific infection and apoptosis of tumor cells.

Benefits of technology

PCV2 can broadly and efficiently infect a variety of human tumor cells, achieving tumor-consuming death, significant oncolytic effect, and high safety, making it suitable for the treatment of various cancers such as lung cancer and cervical cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of PCV2 in preparation of oncolytic viruses, and belongs to the technical field of biological medicines. The invention proposes that PCV2 can be used as an oncolytic virus for the first time, the PCV2 can efficiently infect various human tumor cell lines in a broad-spectrum manner, replication and filial generation virus assembly are completed in cytoplasm, and finally virus particles are released in a cell lysis or apoptosis way. The novel oncolytic virus PCV2 provided by the invention is low in human normal cell tropism and has natural tumor cell tropism. Compared with the traditional virulent oncolytic virus, the PCV2 has a mild killing effect, and mostly realizes tumor depletion death by inhibiting cell growth, limiting tumor energy supply, inhibiting tumor cell migration and invasion and other anti-tumor effects, so that the PCV2 is safer. Through xenotransplantation tumor-bearing mouse model in-vivo experiments, the PCV2 shows an obvious oncolytic effect in lung cancer and cervical cancer, and has an obvious clinical application value.
Need to check novelty before this filing date? Find Prior Art